

Percutaneous Therapy for Aortic & Mitral Valve Disease

Ted Feldman, M.D., FSCAI FACC FESC

Evanston Hospital

16th ANGIOPLASTY SUMMIT

TCT Asia Pacific 2011

April 27-29th

Seoul, Korea

Ted Feldman MD, FACC, FESC, FSCAI

Disclosure Information

The following relationships exist:

Grant support: Abbott, Atritech, BSC,
Edwards, St Jude, WL Gore




Consultant: Abbott, BSC, Coherex, Edwards, Intervale,
Diiachi Sankyo-Lilly, WL Gore

Speaker: Boston Scientific


*Off label use of products and investigational devices
will be discussed in this presentation*

Catheter-Based Mitral Valve Repair


MitraClip System



Clip toward MV



Clip across MV



Leaflets grasped

EVEREST II Randomized Clinical Trial

Demographics

	EVEREST II RCT n=279	2008 STS Database		Isolated 1 st Elective Operation for MR* High Volume Hospitals (>140/Yr)
		Repair	Replace	
Age yrs (mean)	68	60	61	59
≥65 yrs	58%	37%	45%	n/a
≥75 yrs	32%	n/a	n/a	0%
Male Gender	64%			
NYHA Class III or IV	50%	26%	45%	n/a
CHF	86%	41%	58%	n/a
Hypertension	75%	60%	67%	43%
Diabetes Mellitus	9%	13%	23%	6.5%
COPD / Chronic Lung Disease	15%	17%	29%	n/a
EF (mean)	60%	53%	55%	56%


Safety Endpoint: 30 Day MAE

Intention to Treat

30 Day MAE	# (%) Patients experiencing event	
	Percutaneous (N=180)	Surgery (N=94)
Death	2 (1.1%)	2 (2.1%)
Major Stroke	2 (1.1%)	2 (2.1%)
Re-operation of Mitral Valve	0	1 (1.1%)
Urgent / Emergent CV Surgery	4 (2.2%)	4 (4.3%)
Myocardial Infarction	0	0
Renal Failure	1 (0.6%)	0
Deep Wound Infection	0	0
Ventilation > 48 hrs	0	4 (4.3%)
New Onset Permanent Atrial Fib	2 (1.1%)	0
Septicemia	0	0
GI Complication Requiring Surgery	2 (1.1%)	0
Transfusions ≥ 2 units	24 (13.3%)	42 (44.7%)
TOTAL % of Patients with MAE	15.0%	47.9%
Difference (Percutaneous – Surgery) = -32.9% p<0.001; (95% CI: -20.7%, -45.0%)		


Kaplan-Meier Freedom from Death

Intention to Treat




At Risk:	0 Days	6m	1yr	1.5yr	2yr	3yr
Percutaneous	184	166	163	153	133	52
Surgery	95	78	74	71	63	25

Landmark Analysis of Kaplan-Meier Freedom from MV Surgery (Percutaneous)/Re-operation (Surgery) Intention to Treat



At Risk:	0 Days	6m	1yr	1.5yr	2yr	3yr
Percutaneous	184	138	131	124	109	44
Surgery	95	77	72	69	61	24

Endovascular Valve Edge-to-Edge REpair STUDY



Subgroup Analyses for the Primary End Point at 12 Months

Transcatheter Valve Therapy

First Generation Devices



Edwards Sapien™



CoreValve

Transcatheter Aortic Valve Implantation for the Treatment of Severe Symptomatic Aortic Stenosis in Patients at Very High or Prohibitive Surgical Risk

Acute and Late Outcomes of the Multicenter Canadian Experience

Josep Rodés-Cabau, MD,* John G. Webb, MD,† Anson Cheung, MD,† Jian Ye, MD,†

Philippe Pibarot, MD,* Glenn L. Frim, MD,† Michael G. Cole, MD,† Michael J. Ryan, MD,†

Table 1 Baseline Characteristics of the Study Population (n = 339)

Variables	All Patients (n = 339)	Transfemoral (n = 162)	Transapical (n = 177)	p Value
Age (yrs)	81 ± 8	83 ± 8	80 ± 8	0.009
Male sex	152 (44.8)	91 (56.1)	61 (34.5)	<0.0001
BMI (kg/m ²)	26 ± 5	26 ± 5	26 ± 5	0.934
Diabetes	79 (23.3)	37 (22.8)	42 (23.7)	0.898
Dyslipidemia	241 (71.1)	104 (64.2)	137 (77.4)	0.020
Hypertension	252 (74.3)	102 (62.9)	150 (84.7)	<0.0001
Current smokers	20 (5.9)	8 (4.9)	12 (6.8)	0.645
NYHA functional class				

Patient Characteristics - 1



Characteristic	TAVI n=179	Standard Rx n=179	P value
Age - yr	83.1 ± 8.6	83.2 ± 8.3	0.95
Male sex (%)	45.8	46.9	0.92
STS Score	11.2 ± 5.8	12.1 ± 6.1	0.14
Logistic EuroSCORE	26.4 ± 17.2	30.4 ± 19.1	0.04
NYHA			
I or II (%)	7.8	6.1	0.68
III or IV (%)	92.2	93.9	0.68
CAD (%)	67.6	74.3	0.20
Prior MI (%)	18.6	26.4	0.10
Prior CABG (%)	37.4	45.6	0.17
Prior PCI (%)	30.5	24.8	0.31
Prior BAV (%)	16.2	24.4	0.09
CVD (%)	27.4	27.5	1.00

Sex-Associated Differences in Left Ventricular Function in Aortic Stenosis of the Elderly

John D. Carroll, MD; Eugenia P. Carroll, MD; Ted Feldman, MD; David M. Ward, BA; Roberto M. Lang, MD; Dean McGaughey, JD; and Robert B. Karp, MD

Background. In aortic stenosis, the response to compensated hypertrophy to overt heart failure is poorly understood.

Methods and Results. Left ventricular function was compared in 29 men 60 years or older with both hemodynamically significant aortic stenosis and no important coronary artery disease. In women versus men (aortic valve area, 1.0 ± 0.4 versus 1.0 ± 0.4 cm², $p=0.02$), the left ventricle of women had a greater fractional shortening (38 ± 5 versus 28 ± 5 %, $p=0.001$), smaller end-systolic chamber size (1.82 ± 0.4 versus 2.45 ± 0.51 cm, $p=0.01$), lower end-systolic wall stress (210 ± 35 versus 182 ± 29 mm Hg, $p=0.02$), higher mean pulmonary pressure ($1,595 \pm 384$ versus $1,595 \pm 384$ mm Hg/sec, $p=0.02$), higher mean pulmonary flow (1.1 ± 0.2 versus 1.1 ± 0.2 l/min/m², $p=0.02$), higher mean pulmonary resistance (1.1 ± 0.2 versus 1.1 ± 0.2 mm Hg/l/min/m², $p=0.02$), shorter ejection period (340 ± 40 versus 370 ± 40 ms, $p=0.02$), and shorter ejection time (340 ± 40 versus 370 ± 40 ms, $p=0.02$).

Supernormal left ventricular ejection performance was present in 41% of the women and only 14% of the men ($p=0.002$). This subgroup of women had a small, thick-walled chamber (end-diastolic radius to thickness ratio, 1.58 ± 0.52 versus 2.45 ± 0.51 in control women, $p=0.01$) with low end-systolic wall stress. Subnormal ejection performance was present in 64% of the men and only 18% of the women ($p=0.002$). This subgroup of men had an increased chamber size and high end-systolic wall stress compared with control men. Greater left ventricular mass was present in men compared with women (211 ± 55 versus 179 ± 55 g/m², $p=0.03$).

Conclusions. Sex is a factor in left ventricular adaptation to valvular aortic stenosis in adults 60 years or older. (*Circulation* 1992;86:1099-1107)

